Trans-national Access Call: COVID-19 Therapeutics Pipeline
With more than 1.5 million deaths by the end of 2020 and no signs of slowing down, the COVID-19 pandemic is one of the deadliest diseases to plague mankind in recent times. Considerable scientific effort from all over the world has been rallied to fight this common foe.
With this free-of-charge TA Call `COVID-19 Therapeutics Pipeline´, INFRAFRONTIER is providing researchers access to test their innovative and novel COVID-19 therapeutics in a standardised infection pipeline that uses preclinical models to study COVID-19 infection.
Application form: Interested research teams are requested to fill in the application form and send it to email@example.com
Context and aims of the call
Main objective of this INFRAFRONTIER2020 Trans-national Access Call is to provide extensive user support to the selected projects for assessing novel potential vaccine and treatment compounds for COVID-19. As starting material for the TA service, only sufficient amounts of the therapeutic candidate and desired mode of administration will be provided by the TA call users. It will be incumbent upon users to provide these materials and information.
Viral particles, COVID-19 mouse models, cohort production and BSL3 pipeline analysis will be provided by INFRAFRONTIER partners - CIPHE and CCP. Further functional analysis and advanced readouts like organ histopathological analysis, multiplex assay profiling of cytokines and chemokines in lung and mouse serum etc. can be provided on a collaborative basis outside the scope of this TA call. A final infection profile report will be provided as a deliverable.
Please fill in the application form and send it to firstname.lastname@example.org
31 January 2021
This TA Call is free-of-charge for the selected applicants.
Please contact email@example.com if you have any questions.
For more information about this project and about how to apply please visit our website: https://www.infrafrontier.eu/trans-national-access-call-covid-19-therapeutics-pipeline